More MS news articles for April 2002

Betaferon(R)/Betaseron(R) BEYOND Trial Focuses on New High-dose Therapeutic Option for MS

http://globalarchive.ft.com/globalarchive/article.html?id=020416007703

Apr 16, 2002
PR Newswire - USA

Schering AG (FSE: SCH, NYSE: SHR), Germany and its US subsidiary Berlex Laboratories, Inc. today announced that a multinational Phase III trial will commence to assess a new high dose of Betaferon(R)/Betaseron(R) (interferon beta-1b) for SC injection in patients with relapsing-remitting multiple sclerosis (MS). The BEYOND study (Betaseron Efficacy Yielding Outcomes of a New Dose) will be the largest MS trial ever, involving more than 2,000 participants.

"There is a strong body of clinical trial evidence that dose and frequency of administration are important to achieve optimal clinical benefit in MS. These data suggest that higher dose and more frequent dosing of interferon beta result in greater efficacy. With BEYOND, now is the time to investigate whether a dose higher than any currently available interferon can exert an even greater therapeutic effect," said Stuart D. Cook, M.D., President, University of Medicine & Dentistry of New Jersey.

"The goal of BEYOND is to advance interferon therapy to the next level for patients and neurologists. This trial has the true potential to change the current approach to MS treatment," said Dr. Joachim-Friedrich Kapp, Head of Specialised Therapeutics at Schering AG. "The recently published American Academy of Neurology guidelines confirm more than a decade's worth of clinical experience demonstrating the unsurpassed efficacy of high-dose, high-frequency Betaferon(R)/Betaseron(R) in treating relapsing-remitting MS."

About BEYOND

In this multi-center, randomized, blinded study, patients with relapsing- remitting MS will be randomized to receive either Betaferon(R)/Betaseron(R) given every other day as a subcutaneous injection of 500 mcg (16 MIUs) or Betaferon(R)/Betaseron(R) 250 mcg (8 MIUs) every other day (the currently approved dosing regimen). Dose titration will take place over a period of several weeks. In keeping with other large-scale clinical trials, an international steering committee comprised of renowned MS investigators and an independent safety monitoring board will be involved. Patient enrolment is scheduled to begin fourth quarter of 2002.

In addition to BEYOND, Schering has several ongoing studies with Betaferon/Betaseron in potential new indications and new combinations. The company also is developing a number of oral agents to treat MS, and continues to improve upon its successful patient support services. Further details will be presented at the European Neurological Society (ENS) meeting in Berlin, in June.

Schering AG is a research-based pharmaceutical company. Its activities are focused on four business areas: Fertility Control & Hormone Therapy, Diagnostics & Radiopharmaceuticals, Dermatology as well as Specialized Therapeutics for disabling diseases in the fields of the central nervous system, oncology and cardiovascular. As a global player with innovative products Schering AG aims for leading positions in specialized markets worldwide. With in-house R&D and supported by an excellent global network of external partners, Schering AG is securing a promising product pipeline. Using new ideas, Schering AG aims to make a recognized contribution to medical progress and strives to improve the quality of life.Berlex is part of the Schering group. making medicine work your

Contacts: Friedrich von Heyl Peter Vogt Claudia Schmitt Business Communication Investor Relations Pharma Communication office: office: office: +49.30.468.15296 +49.30.468.12838 +49.30.468.15805
In the US: Jeanine O'Kane Joanne Marion Media Relations Investor Relations Tel:001 973 487-2095 001 973 487-2164 Find additional information at: http://www.schering.de/eng

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and Schering AG's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. Certain factors that may cause such differences are discussed in our Form 20-F and Form 6-K reports filed with the U.S. Securities and Exchange Commission. Schering AG undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.

Schering AG; Berlex Laboratories, Inc.
 

All Material Subject to Copyright